首页> 外国专利> Human monoclonal antibodies to programmed death 1 (PD-1) as well as methods of treating cancer using the anti-PD-1 antibodies alone or in combination with other immunotherapies

Human monoclonal antibodies to programmed death 1 (PD-1) as well as methods of treating cancer using the anti-PD-1 antibodies alone or in combination with other immunotherapies

机译:针对程序性死亡1(PD-1)的人类单克隆抗体,以及使用抗PD-1抗体单独或与其他免疫疗法联用的癌症治疗方法

摘要

The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
机译:本发明提供了分离的单克隆抗体,特别是人单克隆抗体,其以高亲和力特异性结合PD-1。还提供了编码本发明抗体的核酸分子,表达载体,宿主细胞和表达本发明抗体的方法。还提供了包含本发明抗体的免疫缀合物,双特异性分子和药物组合物。本发明还提供了使用抗PD-1抗体检测PD-1的方法,以及用于治疗包括癌症和传染病在内的各种疾病的方法。本发明进一步提供了使用联合免疫疗法例如抗CTLA-4抗体和抗PD-1抗体的组合来治疗过度增生性疾病例如癌症的方法。本发明还提供了改变与单独使用此类抗体治疗有关的不良事件的方法。

著录项

  • 公开/公告号NO2018008I2

    专利类型

  • 公开/公告日2018-02-14

    原文格式PDF

  • 申请/专利号NO20180000008C

  • 发明设计人

    申请日2018-02-14

  • 分类号C07K16/28;A61K39/395;

  • 国家 NO

  • 入库时间 2022-08-21 12:50:50

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号